Dr. Scott Freeman, shown with his Committee, successfully defended his dissertation on October 15, 2007. Pictured from left to right: Committee member Srikumar Chellappan; Dissertation Chair David Johnson, University of Texas, M.D. Anderson Cancer Center; Major Professor Doug Cress; Scott; Committee members Eric Haura and Ken Wright.
Dr. Freeman is currently a Senior Medical Writer with Shire Pharmaceuticals.
Dr. Freeman's publication record while in the Program:
Ma Y, Freeman SN, Cress WD. E2F4 Deficiency Promotes Drug-Induced Apoptosis. Cancer Biol Ther. 2004 Dec 14;3(12):1262-9.
Freeman SN, Bepler G, Haura E, Sutphen R, Cress WD. Re: Prognostic significance of short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst. 2005 Jul 20;97(14):1088-9.
Freeman SN, Ma Y, Cress WD.RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis.J Biol Chem. 2008 Jan 25;283(4):2353-62. Epub 2007 Nov 26.
Dr. Freeman's publication record since graduation:
Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA. What the orphan drug act has done lately for children with rare diseases: a 10-year analysis. Pediatrics. 2012 Mar;129(3):516-21.
Freeman SN, and Cress WD. RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biology and Therapy. 2010 Dec 28;10(11).
Freeman SN, Burke KA, Imoisili MA, Coté TR. The Orphan Drug Act and the development of stem cell-based products for rare diseases. Cell Stem Cell. 2010 Sep 3;7(3):283-7.
Burke KA, Freeman SN, Imoisili MA, Coté TR. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review. Clin Pharmacol Ther. 2010 Oct;88(4):449-53. Review.
Freeman SN, Bepler G. RRM1 (Ribonucleotide Reductase M1). Atlas of Genetics and Cytogenetics in Oncology and Haematology. June 2009. URL: http://AtlasGeneticsOncology.org/Genes/RRM1ID42174ch11p15.html